New combo offers hope for Tough-to-Treat leukemia
NCT ID NCT07451912
First seen Mar 12, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) in adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated) who cannot tolerate strong chemotherapy. The goal is to see if this treatment can achieve remission and prevent the cancer from returning. Participants will receive two cycles of induction therapy, and if they respond well, up to four more cycles of consolidation therapy, with regular monitoring for side effects and disease status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.